One patient had an epithelioid IMT that was identified to contain an RANBP2-anaplastic lymphoma kinase (ALK) fusion; he experienced a complete response to crizotinib for 8 months. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.